Yu NY - Search Results

1

Tumor disposition of pegylated liposomal CKD-602 and the reticuloendothelial system in preclinical tumor models.

Zamboni WC, Eiseman JL, Strychor S, Rice PM, Joseph E, Zamboni BA, Donnelly MK, Shurer J, Parise RA, Tonda ME, Yu NY, Basse PH. Zamboni WC, et al. Among authors: yu ny. J Liposome Res. 2011 Mar;21(1):70-80. doi: 10.3109/08982101003754385. Epub 2010 Jun 9. J Liposome Res. 2011. PMID: 20528623

2

Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.

Zamboni WC, Strychor S, Joseph E, Walsh DR, Zamboni BA, Parise RA, Tonda ME, Yu NY, Engbers C, Eiseman JL. Zamboni WC, et al. Among authors: yu ny. Clin Cancer Res. 2007 Dec 1;13(23):7217-23. doi: 10.1158/1078-0432.CCR-07-1035. Clin Cancer Res. 2007. PMID: 18056203

3

Allometric scaling of pegylated liposomal anticancer drugs.

Caron WP, Clewell H, Dedrick R, Ramanathan RK, Davis WL, Yu N, Tonda M, Schellens JH, Beijnen JH, Zamboni WC. Caron WP, et al. J Pharmacokinet Pharmacodyn. 2011 Oct;38(5):653-69. doi: 10.1007/s10928-011-9213-5. Epub 2011 Aug 24. J Pharmacokinet Pharmacodyn. 2011. PMID: 21863380

4

STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models.

Yu NY, Conway C, Pena RL, Chen JY. Yu NY, et al. Anticancer Res. 2007 Jul-Aug;27(4B):2541-5. Anticancer Res. 2007. PMID: 17695551 Free article.

5

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC. Mamidi RN, et al. Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27. Cancer Chemother Pharmacol. 2010. PMID: 20661737

6

Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.

Zalipsky S, Saad M, Kiwan R, Ber E, Yu N, Minko T. Zalipsky S, et al. J Drug Target. 2007 Aug-Sep;15(7-8):518-30. doi: 10.1080/10611860701499946. J Drug Target. 2007. PMID: 17671898

7

Seasonal Impact on Grade ≥2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis.

Rades D, Janssen S, Narvaez-Wolf CA, Kristiansen C, Timke C, Duma MN, Bartscht T, Yu NY. Rades D, et al. Among authors: yu ny. Anticancer Res. 2024 Jun;44(6):2617-2620. doi: 10.21873/anticanres.17067. Anticancer Res. 2024. PMID: 38821595

8

The Role of Radiotherapy for Meningeal Melanocytomas - A 20 Year Update.

Rades D, Zemskova O, Gliemroth J, Yu NY. Rades D, et al. Among authors: yu ny. In Vivo. 2024 May-Jun;38(3):1220-1228. doi: 10.21873/invivo.13558. In Vivo. 2024. PMID: 38688652 Free PMC article.

9

Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in Elderly Lung Cancer Patients.

Rades D, Cremers F, Janssen S, Bartscht T, Kristiansen C, Timke C, Duma MN, Yu NY, Bohnet S. Rades D, et al. Among authors: yu ny. Anticancer Res. 2024 May;44(5):2073-2079. doi: 10.21873/anticanres.17011. Anticancer Res. 2024. PMID: 38677766

10

Tricetin suppresses the cell migration and BMP-6 expression through p38 signaling pathways in human retinal pigment epithelium cells.

Chien HW, Chuang CC, Hsieh YH, Lee CY, Yu NY, Yang SF. Chien HW, et al. Among authors: yu ny. Environ Toxicol. 2024 Apr 23. doi: 10.1002/tox.24294. Online ahead of print. Environ Toxicol. 2024. PMID: 38654487

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

189 results

Search Page